{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:32:41Z","timestamp":1791304361346,"version":"4.3.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ejca.2021.03.017","type":"journal-article","created":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T11:43:32Z","timestamp":1621165412000},"page":"190-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report"],"prefix":"10.1016","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4509-953X","authenticated-orcid":false,"given":"Hee J.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo C.","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok J.","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeong-Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seock A.","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong S.","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung H.","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung S.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyong H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se H.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9713-2605","authenticated-orcid":false,"given":"Hyun-Ah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Hwan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonshik","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3908-2555","authenticated-orcid":false,"given":"Min H.","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sei H.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.03.017_bib1","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(17)30677-0","article-title":"Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study","volume":"18","author":"Fidler","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.03.017_bib2","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1200\/JCO.2015.65.8013","article-title":"Subtype-dependent relationship between young age at diagnosis and breast cancer survival","volume":"34","author":"Partridge","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.03.017_bib3","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.03.017_bib4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11864-017-0473-1","article-title":"Adjuvant endocrine therapy in breast cancer: evolving paradigms in premenopausal women","volume":"18","author":"Rossi","year":"2017","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ejca.2021.03.017_bib5","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1200\/JCO.19.02242","article-title":"Improving adjuvant endocrine treatment tailoring in premenopausal women with hormone receptor-positive breast cancer","volume":"38","author":"Lambertini","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.03.017_bib6","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1093\/annonc\/mdx285","article-title":"Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT","volume":"28","author":"Regan","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.03.017_bib7","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.19.00126","article-title":"Adding ovarian suppression to tamoxifen for premenopausal breast cancer: a randomized phase III trial","volume":"38","author":"Kim","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.03.017_bib8","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1200\/JCO.2006.06.5888","article-title":"American society of clinical oncology recommendations on fertility preservation in cancer patients","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.03.017_bib9","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1001\/jama.2015.17299","article-title":"Prevention of premature menopause and preservation of fertility in young cancer survivors: hopeful though modest long-term results","volume":"314","author":"Partridge","year":"2015","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ejca.2021.03.017_bib10","series-title":"ESHRE guideline: female fertility preservation","first-page":"hoaa052","author":"Anderson","year":"2020"},{"key":"10.1016\/j.ejca.2021.03.017_bib11","first-page":"1664","article-title":"Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines","volume":"31","author":"Lambertini","year":"2020","journal-title":"Hum Reprod Open"},{"key":"10.1016\/j.ejca.2021.03.017_bib12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s12885-016-2354-6","article-title":"The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress","volume":"16","author":"Kim","year":"2016","journal-title":"BMC Canc"},{"key":"10.1016\/j.ejca.2021.03.017_bib13","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.19.00126","article-title":"Adding ovarian suppression to tamoxifen for premenopausal breast cancer: a randomized phase III trial","volume":"38","author":"Kim","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.03.017_bib14","article-title":"Adjuvant therapy for very young women with breast cancer: need for tailored treatments","volume":"44\u201351","author":"Goldhirsch","year":"2001","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.ejca.2021.03.017_bib15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/CCO.0000000000000380","article-title":"Controversies about fertility and pregnancy issues in young breast cancer patients: current state of the art","volume":"29","author":"Lambertini","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ejca.2021.03.017_bib16","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.2010.29.7689","article-title":"Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial","volume":"29","author":"Ganz","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.03.017_bib17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10549-005-9059-x","article-title":"Treatment-induced menstrual changes in very young (<35 years old) breast cancer patients","volume":"96","author":"Kil","year":"2006","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.ejca.2021.03.017_bib18","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1200\/JCO.2005.03.3969","article-title":"Incidence, time course,\u00a0and determinants of menstrual bleeding after breast cancer treatment: a prospective study","volume":"24","author":"Petrek","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.03.017_bib19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00280-013-2227-5","article-title":"Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study","volume":"72","author":"Yoo","year":"2013","journal-title":"Canc Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2021.03.017_bib20","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3109\/0284186X.2016.1155738","article-title":"Risk of chemotherapy-induced amenorrhea in patients with breast cancer: a systematic review and meta-analysis","volume":"55","author":"Zavos","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2021.03.017_bib21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3389\/fonc.2019.00575","article-title":"Impact of taxanes, endocrine therapy, and deleterious germline BRCA mutations on anti-mullerian hormone levels in early breast cancer patients treated with anthracycline- and cyclophosphamide-based chemotherapy","volume":"9","author":"Lambertini","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2021.03.017_bib22","first-page":"2926","article-title":"The magnitude of gonadotoxicity of chemotherapy drugs on ovarian follicles and granulosa cells varies depending upon the category of the drugs and the type of granulosa cells","volume":"30","author":"Yuksel","year":"2015","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejca.2021.03.017_bib23","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/molehr\/gau057","article-title":"Docetaxel induces moderate ovarian toxicity in mice, primarily affecting granulosa cells of early growing follicles","volume":"20","author":"Lopes","year":"2014","journal-title":"Mol Hum Reprod"},{"key":"10.1016\/j.ejca.2021.03.017_bib24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.breast.2017.07.017","article-title":"ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3)","volume":"35","author":"Paluch-Shimon","year":"2017","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2021.03.017_bib25","first-page":"624","article-title":"Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer","volume":"47","author":"Jordan","year":"1987","journal-title":"Canc Res"},{"key":"10.1016\/j.ejca.2021.03.017_bib26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10549-008-0071-9","article-title":"Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer","volume":"115","author":"Han","year":"2009","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.ejca.2021.03.017_bib27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0959-8049(99)00225-7","article-title":"Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients","volume":"36","author":"Poikonen","year":"2000","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.03.017_bib28","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1210\/jc.2006-0331","article-title":"Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation","volume":"91","author":"Hehenkamp","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejca.2021.03.017_bib29","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.fertnstert.2009.03.045","article-title":"Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer","volume":"94","author":"Partridge","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejca.2021.03.017_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.008","article-title":"Anti-mullerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy","volume":"74","author":"Freour","year":"2017","journal-title":"Eur J Canc"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921001842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921001842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:32:11Z","timestamp":1760733131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921001842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":30,"alternative-id":["S0959804921001842"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.03.017","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}